Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 142


A Gain-of-Function Mutation in EPO in Familial Erythrocytosis.

Zmajkovic J, Lundberg P, Nienhold R, Torgersen ML, Sundan A, Waage A, Skoda RC.

N Engl J Med. 2018 Mar 8;378(10):924-930. doi: 10.1056/NEJMoa1709064.


Artesunate shows potent anti-tumor activity in B-cell lymphoma.

Våtsveen TK, Myhre MR, Steen CB, Wälchli S, Lingjærde OC, Bai B, Dillard P, Theodossiou TA, Holien T, Sundan A, Inderberg EM, Smeland EB, Myklebust JH, Oksvold MP.

J Hematol Oncol. 2018 Feb 20;11(1):23. doi: 10.1186/s13045-018-0561-0.


Hypoxia promotes IL-32 expression in myeloma cells, and high expression is associated with poor survival and bone loss.

Zahoor M, Westhrin M, Aass KR, Moen SH, Misund K, Psonka-Antonczyk KM, Giliberto M, Buene G, Sundan A, Waage A, Sponaas AM, Standal T.

Blood Adv. 2017 Dec 13;1(27):2656-2666. doi: 10.1182/bloodadvances.2017010801. eCollection 2017 Dec 26.


TGF-β contamination of purified recombinant GDF15.

Olsen OE, Skjærvik A, Størdal BF, Sundan A, Holien T.

PLoS One. 2017 Nov 21;12(11):e0187349. doi: 10.1371/journal.pone.0187349. eCollection 2017.


Cytotoxicity of Poly(Alkyl Cyanoacrylate) Nanoparticles.

Sulheim E, Iversen TG, To Nakstad V, Klinkenberg G, Sletta H, Schmid R, Hatletveit AR, Wågbø AM, Sundan A, Skotland T, Sandvig K, Mørch Ý.

Int J Mol Sci. 2017 Nov 18;18(11). pii: E2454. doi: 10.3390/ijms18112454.


Monitoring multiple myeloma by quantification of recurrent mutations in serum.

Rustad EH, Coward E, Skytøen ER, Misund K, Holien T, Standal T, Børset M, Beisvag V, Myklebost O, Meza-Zepeda LA, Dai HY, Sundan A, Waage A.

Haematologica. 2017 Jul;102(7):1266-1272. doi: 10.3324/haematol.2016.160564. Epub 2017 Apr 6.


Hydroxychloroquine potentiates carfilzomib toxicity towards myeloma cells.

Baranowska K, Misund K, Starheim KK, Holien T, Johansson I, Darvekar S, Buene G, Waage A, Bjørkøy G, Sundan A.

Oncotarget. 2016 Oct 25;7(43):70845-70856. doi: 10.18632/oncotarget.12226.


Caspase-8 regulates the expression of pro- and anti-inflammatory cytokines in human bone marrow-derived mesenchymal stromal cells.

Moen SH, Westhrin M, Zahoor M, Nørgaard NN, Hella H, Størdal B, Sundan A, Nilsen NJ, Sponaas AM, Standal T.

Immun Inflamm Dis. 2016 Jul 21;4(3):327-37. doi: 10.1002/iid3.117. eCollection 2016 Sep.


Erythropoietin (EPO)-receptor signaling induces cell death of primary myeloma cells in vitro.

Våtsveen TK, Sponaas AM, Tian E, Zhang Q, Misund K, Sundan A, Børset M, Waage A, Brede G.

J Hematol Oncol. 2016 Aug 31;9(1):75. doi: 10.1186/s13045-016-0306-x.


Intracellular glutathione determines bortezomib cytotoxicity in multiple myeloma cells.

Starheim KK, Holien T, Misund K, Johansson I, Baranowska KA, Sponaas AM, Hella H, Buene G, Waage A, Sundan A, Bjørkøy G.

Blood Cancer J. 2016 Jul 15;6(7):e446. doi: 10.1038/bcj.2016.56.


VOLIN and KJON-Two novel hyperdiploid myeloma cell lines.

Våtsveen TK, Børset M, Dikic A, Tian E, Micci F, Lid AH, Meza-Zepeda LA, Coward E, Waage A, Sundan A, Kuehl WM, Holien T.

Genes Chromosomes Cancer. 2016 Nov;55(11):890-901. doi: 10.1002/gcc.22388. Epub 2016 Jul 12.


A-kinase anchoring protein AKAP95 is a novel regulator of ribosomal RNA synthesis.

Marstad A, Landsverk OJ, Strømme O, Otterlei M, Collas P, Sundan A, Brede G.

FEBS J. 2016 Feb;283(4):757-70. doi: 10.1111/febs.13630. Epub 2016 Jan 16.


Direct inhibition of c-Myc-Max heterodimers by celastrol and celastrol-inspired triterpenoids.

Wang H, Teriete P, Hu A, Raveendra-Panickar D, Pendelton K, Lazo JS, Eiseman J, Holien T, Misund K, Oliynyk G, Arsenian-Henriksson M, Cosford ND, Sundan A, Prochownik EV.

Oncotarget. 2015 Oct 20;6(32):32380-95. doi: 10.18632/oncotarget.6116.


PDL1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD1-PDL1 Therapy.

Sponaas AM, Moharrami NN, Feyzi E, Standal T, Holth Rustad E, Waage A, Sundan A.

PLoS One. 2015 Oct 7;10(10):e0139867. doi: 10.1371/journal.pone.0139867. eCollection 2015.


The Impact of Chain Length and Flexibility in the Interaction between Sulfated Alginates and HGF and FGF-2.

Arlov Ø, Aachmann FL, Feyzi E, Sundan A, Skjåk-Bræk G.

Biomacromolecules. 2015 Nov 9;16(11):3417-24. doi: 10.1021/acs.biomac.5b01125. Epub 2015 Oct 2.


The natural compound forskolin synergizes with dexamethasone to induce cell death in myeloma cells via BIM.

Follin-Arbelet V, Misund K, Naderi EH, Ugland H, Sundan A, Blomhoff HK.

Sci Rep. 2015 Aug 26;5:13001. doi: 10.1038/srep13001.


Growth differentiation factor 15 (GDF15) promotes osteoclast differentiation and inhibits osteoblast differentiation and high serum GDF15 levels are associated with multiple myeloma bone disease.

Westhrin M, Moen SH, Holien T, Mylin AK, Heickendorff L, Olsen OE, Sundan A, Turesson I, Gimsing P, Waage A, Standal T.

Haematologica. 2015 Dec;100(12):e511-4. doi: 10.3324/haematol.2015.124511. Epub 2015 Aug 20. No abstract available.


Allelic mutations in noncoding genomic sequences construct novel transcription factor binding sites that promote gene overexpression.

Tian E, Børset M, Sawyer JR, Brede G, Våtsveen TK, Hov H, Waage A, Barlogie B, Shaughnessy JD Jr, Epstein J, Sundan A.

Genes Chromosomes Cancer. 2015 Nov;54(11):692-701. doi: 10.1002/gcc.22280. Epub 2015 Jul 29.


MYC amplifications in myeloma cell lines: correlation with MYC-inhibitor efficacy.

Holien T, Misund K, Olsen OE, Baranowska KA, Buene G, Børset M, Waage A, Sundan A.

Oncotarget. 2015 Sep 8;6(26):22698-705.


Activin A inhibits BMP-signaling by binding ACVR2A and ACVR2B.

Olsen OE, Wader KF, Hella H, Mylin AK, Turesson I, Nesthus I, Waage A, Sundan A, Holien T.

Cell Commun Signal. 2015 Jun 6;13:27. doi: 10.1186/s12964-015-0104-z.


The proportion of CD16(+)CD14(dim) monocytes increases with tumor cell load in bone marrow of patients with multiple myeloma.

Sponaas AM, Moen SH, Liabakk NB, Feyzi E, Holien T, Kvam S, Grøseth LA, Størdal B, Buene G, Espevik T, Waage A, Standal T, Sundan A.

Immun Inflamm Dis. 2015 Jun;3(2):94-102. doi: 10.1002/iid3.53. Epub 2015 Mar 2.


BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis.

Rustad EH, Dai HY, Hov H, Coward E, Beisvag V, Myklebost O, Hovig E, Nakken S, Vodák D, Meza-Zepeda LA, Sandvik AK, Wader KF, Misund K, Sundan A, Aarset H, Waage A.

Blood Cancer J. 2015 Mar 20;5:e299. doi: 10.1038/bcj.2015.24.


Modulation of cell metabolic pathways and oxidative stress signaling contribute to acquired melphalan resistance in multiple myeloma cells.

Zub KA, Sousa MM, Sarno A, Sharma A, Demirovic A, Rao S, Young C, Aas PA, Ericsson I, Sundan A, Jensen ON, Slupphaug G.

PLoS One. 2015 Mar 13;10(3):e0119857. doi: 10.1371/journal.pone.0119857. eCollection 2015.


Perturbation of the c-Myc-Max protein-protein interaction via synthetic α-helix mimetics.

Jung KY, Wang H, Teriete P, Yap JL, Chen L, Lanning ME, Hu A, Lambert LJ, Holien T, Sundan A, Cosford ND, Prochownik EV, Fletcher S.

J Med Chem. 2015 Apr 9;58(7):3002-24. doi: 10.1021/jm501440q. Epub 2015 Mar 30.


The role of bone morphogenetic proteins in myeloma cell survival.

Holien T, Sundan A.

Cytokine Growth Factor Rev. 2014 Jun;25(3):343-50. doi: 10.1016/j.cytogfr.2014.04.009. Epub 2014 May 9. Review.


Heparin-like properties of sulfated alginates with defined sequences and sulfation degrees.

Arlov Ø, Aachmann FL, Sundan A, Espevik T, Skjåk-Bræk G.

Biomacromolecules. 2014 Jul 14;15(7):2744-50. doi: 10.1021/bm500602w. Epub 2014 Jun 20.


Identification of the source of elevated hepatocyte growth factor levels in multiple myeloma patients.

Rampa C, Tian E, Våtsveen TK, Buene G, Slørdahl TS, Børset M, Waage A, Sundan A.

Biomark Res. 2014 Apr 9;2(1):8. doi: 10.1186/2050-7771-2-8.


Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin.

Olsen OE, Wader KF, Misund K, Våtsveen TK, Rø TB, Mylin AK, Turesson I, Størdal BF, Moen SH, Standal T, Waage A, Sundan A, Holien T.

Blood Cancer J. 2014 Mar 21;4:e196. doi: 10.1038/bcj.2014.16.


Targeting proliferating cell nuclear antigen and its protein interactions induces apoptosis in multiple myeloma cells.

Müller R, Misund K, Holien T, Bachke S, Gilljam KM, Våtsveen TK, Rø TB, Bellacchio E, Sundan A, Otterlei M.

PLoS One. 2013 Jul 31;8(7):e70430. doi: 10.1371/journal.pone.0070430. Print 2013.


Lymphoma and myeloma cells are highly sensitive to growth arrest and apoptosis induced by artesunate.

Holien T, Olsen OE, Misund K, Hella H, Waage A, Rø TB, Sundan A.

Eur J Haematol. 2013 Oct;91(4):339-46. doi: 10.1111/ejh.12176. Epub 2013 Aug 20.


HGF and IGF-1 synergize with SDF-1α in promoting migration of myeloma cells by cooperative activation of p21-activated kinase.

Rø TB, Holien T, Fagerli UM, Hov H, Misund K, Waage A, Sundan A, Holt RU, Børset M.

Exp Hematol. 2013 Jul;41(7):646-55. doi: 10.1016/j.exphem.2013.03.002. Epub 2013 Mar 14.


Death of multiple myeloma cells induced by cAMP-signaling involves downregulation of Mcl-1 via the JAK/STAT pathway.

Follin-Arbelet V, Torgersen ML, Naderi EH, Misund K, Sundan A, Blomhoff HK.

Cancer Lett. 2013 Jul 28;335(2):323-31. doi: 10.1016/j.canlet.2013.02.042. Epub 2013 Feb 26.


A method for measurement of drug sensitivity of myeloma cells co-cultured with bone marrow stromal cells.

Misund K, Baranowska KA, Holien T, Rampa C, Klein DC, Børset M, Waage A, Sundan A.

J Biomol Screen. 2013 Jul;18(6):637-46. doi: 10.1177/1087057113478168. Epub 2013 Feb 27.


Oncogene addiction to c-MYC in myeloma cells.

Holien T, Sundan A.

Oncotarget. 2012 Aug;3(8):739-40. No abstract available.


Addiction to c-MYC in multiple myeloma.

Holien T, Våtsveen TK, Hella H, Waage A, Sundan A.

Blood. 2012 Sep 20;120(12):2450-3. Epub 2012 Jul 17.


Immunohistochemical analysis of hepatocyte growth factor and c-Met in plasma cell disease.

Wader KF, Fagerli UM, Børset M, Lydersen S, Hov H, Sundan A, Bofin A, Waage A.

Histopathology. 2012 Feb;60(3):443-51. doi: 10.1111/j.1365-2559.2011.04112.x.


Imatinib inhibits proliferation of human mesenchymal stem cells and promotes early but not late osteoblast differentiation in vitro.

Jönsson S, Hjorth-Hansen H, Olsson B, Wadenvik H, Sundan A, Standal T.

J Bone Miner Metab. 2012 Jan;30(1):119-23. doi: 10.1007/s00774-011-0323-3. Epub 2011 Oct 14.


Bone morphogenetic proteins induce apoptosis in multiple myeloma cells by Smad-dependent repression of MYC.

Holien T, Våtsveen TK, Hella H, Rampa C, Brede G, Grøseth LA, Rekvig M, Børset M, Standal T, Waage A, Sundan A.

Leukemia. 2012 May;26(5):1073-80. doi: 10.1038/leu.2011.263. Epub 2011 Sep 23. Erratum in: Leukemia. 2012 May;26(5):1154.


Cyclic AMP induces apoptosis in multiple myeloma cells and inhibits tumor development in a mouse myeloma model.

Follin-Arbelet V, Hofgaard PO, Hauglin H, Naderi S, Sundan A, Blomhoff R, Bogen B, Blomhoff HK.

BMC Cancer. 2011 Jul 18;11:301. doi: 10.1186/1471-2407-11-301.


Serum/glucocorticoid-regulated kinase 1 (SGK1) is a prominent target gene of the transcriptional response to cytokines in multiple myeloma and supports the growth of myeloma cells.

Fagerli UM, Ullrich K, Stühmer T, Holien T, Köchert K, Holt RU, Bruland O, Chatterjee M, Nogai H, Lenz G, Shaughnessy JD Jr, Mathas S, Sundan A, Bargou RC, Dörken B, Børset M, Janz M.

Oncogene. 2011 Jul 14;30(28):3198-206. doi: 10.1038/onc.2011.79. Epub 2011 Apr 11.


Soluble c-Met in serum of patients with multiple myeloma: correlation with clinical parameters.

Wader KF, Fagerli UM, Holt RU, Børset M, Sundan A, Waage A.

Eur J Haematol. 2011 Nov;87(5):394-9. doi: 10.1111/j.1600-0609.2011.01622.x. Epub 2011 Aug 16.


Association between high plasma levels of hepatocyte growth factor and progression of radiographic damage in the joints of patients with rheumatoid arthritis.

Grandaunet B, Syversen SW, Hoff M, Sundan A, Haugeberg G, van Der Heijde D, Kvien TK, Standal T.

Arthritis Rheum. 2011 Mar;63(3):662-9. doi: 10.1002/art.30163.


CpG-oligodeoxynucleotide inhibits Smad-dependent bone morphogenetic protein signaling: effects on myeloma cell apoptosis and in vitro osteoblastogenesis.

Nørgaard NN, Holien T, Jönsson S, Hella H, Espevik T, Sundan A, Standal T.

J Immunol. 2010 Sep 15;185(6):3131-9. doi: 10.4049/jimmunol.0903605. Epub 2010 Aug 11.


Second-generation TKI dasatinib inhibits proliferation of mesenchymal stem cells and osteoblast differentiation in vitro.

Jönsson S, Hjorth-Hansen H, Olsson B, Wadenvik H, Sundan A, Standal T.

Leukemia. 2010 Jul;24(7):1357-9. doi: 10.1038/leu.2010.84. Epub 2010 May 20. No abstract available.


FGFR3 is expressed and is important for survival in INA-6, a human myeloma cell line without a t(4;14).

Våtsveen TK, Brenne AT, Dai HY, Waage A, Sundan A, Børset M.

Eur J Haematol. 2009 Nov;83(5):471-6. doi: 10.1111/j.1600-0609.2009.01312.x. Epub 2009 Jul 6.


OH-2, a hyperdiploid myeloma cell line without an IGH translocation, has a complex translocation juxtaposing MYC near MAFB and the IGK locus.

Våtsveen TK, Tian E, Kresse SH, Meza-Zepeda LA, Gabrea A, Glebov O, Dai HY, Sundan A, Kuehl WM, Børset M.

Leuk Res. 2009 Dec;33(12):1670-7. doi: 10.1016/j.leukres.2009.03.001. Epub 2009 Apr 23.


High expression of BCL3 in human myeloma cells is associated with increased proliferation and inferior prognosis.

Brenne AT, Fagerli UM, Shaughnessy JD Jr, Våtsveen TK, Rø TB, Hella H, Zhan F, Barlogie B, Sundan A, Børset M, Waage A.

Eur J Haematol. 2009 May;82(5):354-63. doi: 10.1111/j.1600-0609.2009.01225.x. Epub 2009 Jan 13.


c-Met signaling promotes IL-6-induced myeloma cell proliferation.

Hov H, Tian E, Holien T, Holt RU, Våtsveen TK, Fagerli UM, Waage A, Børset M, Sundan A.

Eur J Haematol. 2009 Apr;82(4):277-87. doi: 10.1111/j.1600-0609.2009.01212.x. Epub 2009 Jan 6.


IL-10 enhances MD-2 and CD14 expression in monocytes and the proteins are increased and correlated in HIV-infected patients.

Sandanger Ø, Ryan L, Bohnhorst J, Iversen AC, Husebye H, Halaas Ø, Landrø L, Aukrust P, Frøland SS, Elson G, Visintin A, Øktedalen O, Damås JK, Sundan A, Golenbock D, Espevik T.

J Immunol. 2009 Jan 1;182(1):588-95.


Mn2+ regulates myeloma cell adhesion differently than the proadhesive cytokines HGF, IGF-1, and SDF-1alpha.

Slørdahl TS, Hov H, Holt RU, Baykov V, Syversen T, Sundan A, Waage A, Børset M.

Eur J Haematol. 2008 Dec;81(6):437-47. doi: 10.1111/j.1600-0609.2008.01148.x. Epub 2008 Sep 4.


Supplemental Content

Loading ...
Support Center